2024-03-29 08:30:48
A groundbreaking clinical trial led by researchers from Massachusetts General Hospital provides promising insights into the management of metabolic-associated fatty liver disease (MASLD), the most prevalent chronic liver condition in the United States.
The study, published in JAMA, highlights the potential of aspirin as a low-cost treatment option for fatty liver disease associated with metabolic dysfunction, which affects up to one-third of adults in the United States.
Lead author Andrew T. Chan conducted a phase 2 trial that included 80 adults with metabolically impaired fatty liver disease who were randomly assigned to receive daily low-dose aspirin or a placebo for six months.
The results revealed a significant reduction in liver fat content among participants who took aspirin, compared to those who took a placebo. Furthermore, aspirin was considered safe and well-tolerated, with improvements observed in various markers of liver health.
Lead author Tracey Simon confirmed the continued benefits of aspirin across several non-invasive tests, suggesting its potential to mitigate long-term complications associated with metabolic dysfunction-associated fatty liver disease.
While further studies are warranted to confirm the sustained efficacy of aspirin in the management of this disease, these results represent a critical step toward meeting the urgent need for effective treatments for this common liver disease.
Suggest a correction
2024-03-29 08:30:48